Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

Insulin, sulfonylureas, and TZDs are diabetes medications that may cause weight gain. But some, like metformin, may have weight loss potential. Others may be neutral to any weight changes. Weight ...

Type 2 diabetes and obesity are intimately linked; reduction of bodyweight improves glycemic control, mortality and morbidity. Treating obesity in the diabetic is hampered as some diabetic ...

Lidia Ghisdal, MD; Steven Van Laecke, MD; Marc J. Abramowicz, MD, PHD; Raymond Vanholder, MD, PHD; Daniel Abramowicz, MD, PHD ...